Individually Tailored Vs. Standardized Substrate Modification During Radiofrequency Catheter Ablation for Atrial Fibrillation: a Randomized Study
Overview
Physiology
Authors
Affiliations
Aims: This randomized single-centre study sought to compare the efficacy and safety of pulmonary vein isolation (PVI) plus voltage-guided ablation vs. PVI with or without linear ablation depending on the type of atrial fibrillation (AF).
Methods And Results: Overall, 124 ablation-naive patients with paroxysmal or persistent AF were randomized to PVI with (persistent AF) or without (paroxysmal AF) additional linear ablation (control group) vs. PVI plus ablation of low-voltage areas (LVAs) irrespective of AF type. Bipolar voltage mapping was performed during stable sinus rhythm. An LVA consisted of ≥ 3 adjacent mapping points that each had a peak-to-peak amplitude ≤0.5 mV. After a mean follow-up of 12 ± 3 months, significantly more patients in the LVA ablation group were free from atrial arrhythmia recurrence >30 s off antiarrhythmic drugs (AADs) after a single procedure (primary endpoint) compared with control group patients [40/59 (68%) vs. 25/59 (42%), log-rank P = 0.003]. Arrhythmia-free survival on or off AADs was found in 33/59 control group patients (56%) and in 41/59 LVA ablation group patients (70%) (adjusted log-rank P = 0.10). During the 7 day Holter monitoring period at 12 months, significantly more patients in the LVA ablation group were free from arrhythmia recurrence on or off AADs [45/50 (90%) vs. 33/46 (72%), P = 0.04]. No between-group differences were observed regarding procedure duration, fluoroscopy time, and major complications.
Conclusion: In this single-centre study, individually tailored substrate modification guided by voltage mapping was associated with a significantly higher arrhythmia-free survival rate compared with a conventional approach applying linear ablation according to AF type.
Integrated Management of Persistent Atrial Fibrillation.
Yue X, Zhou L, Zhao C Biomedicines. 2025; 13(1).
PMID: 39857675 PMC: 11760448. DOI: 10.3390/biomedicines13010091.
Gigli L, Preda A, Coluzzi D, Sartore M, Vila M, Carbonaro M Front Physiol. 2024; 15:1474568.
PMID: 39665050 PMC: 11631849. DOI: 10.3389/fphys.2024.1474568.
Sciacca V, Sohns C, Crijns H, Marrouche N, Schramm R, Moersdorf M Eur J Heart Fail. 2024; 27(2):255-263.
PMID: 39444312 PMC: 11860721. DOI: 10.1002/ejhf.3505.
[Initial ablation of atrial fibrillation-Is pulmonary vein isolation sufficient? : Pro and contra].
Chun K, Rolf S Herzschrittmacherther Elektrophysiol. 2024; 35(4):268-273.
PMID: 39331144 DOI: 10.1007/s00399-024-01044-8.
Valcher S, Villaschi A, Falasconi G, Chiarito M, Giunti F, Novelli L J Clin Med. 2024; 13(15).
PMID: 39124807 PMC: 11313645. DOI: 10.3390/jcm13154541.